Question · asked by 1 review

CLOZAPINE + ZIPRASIDONE vs CLOZAPINE + QUETIAPINE (Wen 2015): Leaving the study early

Population
people with treatment‐resistant schizophrenia
Intervention
CLOZAPINE + ZIPRASIDONE
Comparison
CLOZAPINE + QUETIAPINE (Wen 2015)
Outcome
Leaving the study early

It is very uncertain whether CLOZAPINE + ZIPRASIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Wen 2015) (very low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
CLOZAPINE + ZIPRASIDONE vs CLOZAPINE + QUETIAPINE (Wen 2015)
Leaving the study early: acceptability of treatment ‐ as measured by completion of trial · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ZIPRASIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Wen 2015) (very low certainty).
Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane Headline outcomes only
RR 0.52 [0.05, 5.41]1 study · 63 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia
2017 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.